Lexicon Pharmaceuticals’ (LXRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $4.00 price target on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued reports about the stock. StockNews.com initiated coverage on shares […]